Europe's Agritech Crown Is Slipping: What a New Report Reveals

Jan de Vries · 2026-10-30

The Netherlands has long been the quiet overachiever of European agriculture. Tiny country, massive output—it's the world's second-largest agricultural exporter by value, right after the US. But a new report from Invest-NL, the Dutch national investment institution, suggests that crown is starting to wobble. The report, titled *Deep Dive Agrifood Biotech*, warns that while the Netherlands still excels at generating scientific innovation, it's losing ground when it comes to turning that brilliance into commercial scale. In other words: great at starting, not so great at finishing. ### The Scale-Up Gap Here's a stat that stopped me in my tracks: the Netherlands accounts for 3.3% of biotech startups worldwide, but only 1.3% of scale-ups. That's according to broader biotech data from TNO cited in the report. So the country is producing plenty of promising young companies—but far too few are growing into global players. Invest-NL identifies three recurring bottlenecks: - Too few promising technologies become scalable ventures. - Regulatory and validation processes delay market entry. - Insufficient financing prevents companies from reaching industrial production. It's a familiar story across Europe, but the stakes here are particularly high. The report estimates that addressing these barriers could unlock roughly $18.5 billion (€17 billion) in additional annual revenue by 2040. In a favorable scenario, Dutch agrifood biotech revenues could hit about $27 billion (€25 billion) annually by 2040, compared with just $9–10 billion (€8–9 billion) if current conditions persist. ### Ten Years to Say Yes One of the most striking obstacles involves biological crop protection—alternatives to conventional chemical pesticides. Getting European regulatory approval for a new biological product can take eight to ten years. That's not a typo. Existing frameworks were largely designed around chemicals, making them a poor fit for biological innovations. As a result, some Dutch companies are launching in Brazil and the United States first, where commercialization moves faster. Invest-NL warns that Europe risks losing ground in a biological crop protection market that could expand seven- to tenfold by 2040. Food biotechnology faces similar hurdles. Regulatory approval for novel ingredients can take one to three years longer in Europe than in the US. And building a first commercial production facility can require tens or even hundreds of millions of dollars. For fermentation-derived food ingredients alone, favorable conditions could support about $8.7 billion (€8 billion) in annual Dutch revenues by 2040, versus around $2.2 billion (€2 billion) under existing policies. ### What's the Fix? The report stresses that faster approvals shouldn't come at the expense of safety. Instead, regulators should offer earlier guidance, more predictable assessments, and opportunities for companies to validate products under real-world conditions. Crucially, the Netherlands doesn't need to manufacture everything domestically. The smarter play is to retain strategically valuable knowledge, intellectual property, companies, and specialized capabilities—while tapping into European production networks where it makes sense. As one entrepreneur interviewed for the report put it: "We don't need to own the factory. We need to own the idea and the company that scales it." That's the shift in mindset Invest-NL is pushing for. And with the right coordination on regulation, financing, and commercialization, the Netherlands could turn its scientific edge into a commercial one. But the window is closing. Innovation isn't the issue. Turning it into industrial-scale success is. And right now, Europe—and the Netherlands in particular—is leaving that job half-finished.